Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine (EB-1020) in pediatric ADHD
NCT07087327Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of centanafadine in attention deficit hyperactivity disorder (ADHD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07087327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087327.